Medical Affairs Leader Dr. Kirk Shepard Joins BP Logix’s Life Sciences Strategic Advisory Board

Renowned Medical Affairs executive and MAPS co-founder Dr. Kirk Shepard steps up to help guide the next wave of digital innovation in the life sciences sector.

SAN DIEGO--(BUSINESS WIRE)--As part of its mission to drive innovation in Medical Affairs automation, BP Logix is pleased to announce the appointment of Dr. Kirk Shepard to the company's Life Sciences Strategic Advisory Board.

Dr. Shepard is a globally recognized expert in Medical Affairs who brings more than 30 years of deep operational knowledge and thought leadership to the Advisory Board.

He currently serves as Chief Medical Officer at PDS Biotech. His prior roles include Chief Medical Officer and Head of Global Medical Affairs Oncology at Eisai, as well as senior leadership positions at Takeda, Boehringer Ingelheim, Baxter, and Baxalta.

He is also a co-founder and former President of the Medical Affairs Professional Society (MAPS), which boasts more than 15,000 members. His upcoming book, Voices of Oncology (Forbes Books, September 2025), captures insights from global cancer care leaders and reflects his deep commitment to cross-functional collaboration and patient-centered innovation. Together, these efforts to elevate the Medical Affairs profession highlight the depth of expertise Dr. Shepard brings to the BP Logix Advisory Board.

"Dr. Shepard has spent his career building world-class Medical Affairs functions that bridge science, strategy, and patient impact," said Girish Pashilkar, CEO of BP Logix. "His voice will be invaluable as we continue designing solutions that meet the evolving needs of Medical Affairs teams in complex, high-stakes environments."

Dr. Shepard joins current Advisory Board members Dr. Jethro Ekuta and Dr. Rob Kaper, continuing BP Logix’s commitment to working directly with industry leaders to shape the future of automation in Medical Affairs.

"The role of Medical Affairs has expanded dramatically. It now requires cross-functional alignment, real-time insights, and digital agility to succeed," said Dr. Shepard. "BP Logix understands that complexity. Their technology is built for how Medical Affairs teams actually operate: across silos, under scrutiny, and always with science at the center. I’m honored to contribute to their mission."

As Strategic Advisors, Dr. Shepard and his fellow board members will help guide BP Logix’s product strategy, industry partnerships, and customer engagement in the life sciences sector.

"This board isn’t ceremonial. It’s hands-on, practical, and grounded in lived experience," added Pashilkar. "We’re grateful to have Dr. Shepard join us in that effort."

To learn more about BP Logix and its solutions for mission-critical processes in Medical Affairs, visit www.bplogix.com.